<DOC>
	<DOCNO>NCT01894919</DOCNO>
	<brief_summary>The aim extension study explore antibody persistence 24 36 month last dose vaccine , infant receive two three dose primary series plus booster dose 11 month age , Novartis meningococcal B vaccine ( rMenB + OMV NZ ) group I III parent V72_28 study . This study also explore antibody persistence 24 36 month two catch-up dos Novartis meningococcal B vaccine ( rMenB + OMV NZ ) administer child ( 2 10 year old ) group IV parent V72_28 study .</brief_summary>
	<brief_title>Antibody Persistence , Safety Tolerability Booster Dose Meningococcal B Vaccine After Completion Vaccination Course Study V72_28</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>For naïve subject newly enrol : 1 . Healthy infant child accord follow age group : 1 . Healthy subject 35 47 month age , ( applicable group K ) ( The age window define first day subject turn 35 month age day subject turn 48 month age ) , 2 . Healthy subject 4 7 year age ( applicable group L ) ( The age window define first day subject turn 4 year age day subject turn 8 year age ) . 3 . Healthy subject 8 12 year age ( applicable group M ) ( The age window define first day subject turn 8 year age day subject turn 13 year age ) . 2. parent/legal guardian give write informed consent nature study explain ; 3. parent/legal guardian confirm availability visit schedule study ; 4. good health determine medical history , physical examination , clinical judgment investigator . For Subjects participate V72_28 study ( Followon Subjects ) : 1. parent/legal guardian give write informed consent nature study explain ; 2. parent/legal guardian confirm availability visit schedule study ; 3. good health determine medical history , physical examination , clinical judgment investigator 4. complete vaccination course V72_28 study receive last vaccination 24 36 month enrollment V72_28E1 For naïve subject newly enrol : 1 . History serogroup B meningococcal vaccine administration ; 2 . Previous know suspected disease cause N. meningitidis ; 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection colonization ; 4 . History severe allergic reaction previous vaccination hypersensitivity component vaccine ; 5 . Pregnancy nursing ( breastfeed ) mother ; 6 . Females childbearing age use plan use acceptable birth control measure , duration study . Oral , inject implanted hormonal contraceptive , barrier method ( condom diaphragm spermicide ) , intrauterine device , surgical sterilization , transdermal delivery , congenital sterility sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least two month prior study entry ; 7 . Known suspected autoimmune disease impairment/alteration immune system result ( example ) : Receipt chronic immunosuppressive therapy Receipt chronic immunostimulants Immune deficiency disorder , know HIV infection 8 . History seizure , progressive neurological disease Guillain Barré Syndrome ( exception : one selflimited febrile seizure acceptable ) . 9 . Known bleed diathesis condition may associate prolonged bleeding time . 10 . Subject 's parent ( ) legal guardian ( ) able comprehend follow require study procedure whole period study . 11 . Intent participate another clinical study study . 12 . Family member household member study staff ; 13 . History illness/condition , opinion investigator , might interfere evaluation study objective pose additional risk subject due participation study . 14 . Any significant chronic infection . 15 . Any serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . For Subjects participate V72_28 study ( Followon Subjects ) : Exclusion criterion naïve subject , exception criterion 1 .</criteria>
	<gender>All</gender>
	<minimum_age>35 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Meningococcal B disease ,</keyword>
	<keyword>Antibody persistence</keyword>
</DOC>